2. Academic Validation
  3. A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial

A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial

  • Oncologist. 2019 Dec;24(12):e1409-e1416. doi: 10.1634/theoncologist.2018-0518.
David R Spigel 1 2,  Dianna L Shipley 3 2,  David M Waterhouse 3 4,  Suzanne F Jones 3,  Patrick J Ward 3 4,  Kent C Shih 3 2,  Brian Hemphill 3 2,  Michael McCleod 3 5,  Robert C Whorf 3 6,  Ray D Page 3 7,  Joseph Stilwill 3 8,  Tarek Mekhail 9,  Cindy Jacobs 10,  Howard A Burris 3rd 3 2,  John D Hainsworth 3 2
Affiliations

Affiliations

  • 1 Sarah Cannon Research Institute, Nashville, Tennessee, USA [email protected].
  • 2 Tennessee Oncology, PLLC, Nashville, Tennessee, USA.
  • 3 Sarah Cannon Research Institute, Nashville, Tennessee, USA.
  • 4 Oncology Hematology Care, Cincinnati, Ohio, USA.
  • 5 Florida Cancer Specialists, Ft. Myers Florida, USA.
  • 6 Florida Cancer Specialists, Bradenton, Florida, USA.
  • 7 Center for Cancer and Blood Disorders, Ft. Worth, Texas, USA.
  • 8 Research Medical Center, Kansas City, Missouri, USA.
  • 9 Florida Hospital Cancer Institute, Orlando, Florida, USA.
  • 10 Oncogenex, Bothell, Washington, USA.
PMID: 31420467 DOI: 10.1634/theoncologist.2018-0518
Keywords

Heat‐shock protein 27; Non‐small cell lung cancer; Oligonucleotide.

Figures
Products